Microsatellite instability and therapeutic consequences in colorectal cancer
Related Experiment Video
Updated: May 21, 2026
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
1Molecular Gastroenterology Unit, IRCCS Istituto Clinico Humanitas, Rozzano, Italy. luigi.laghi@humanitas.it
Abstract:
Microsatellite instability (MSI), the molecular phenotype of colorectal cancers with mismatch repair defects was discovered in the last decade of the previous century. As a field of investigation which successfully joins basic and clinical science, MSI is an example of real translational science, starting from the molecular basis of a disease and extending to the clinical arena. In clinical settings, MSI is a diagnostic biomarker leading to the diagnosis of hereditary nonpolyposis colorectal cancer. However, the clinical implication of MSI testing extends to the role of prognostic marker, due to the better outcome of patients with MSI colorectal cancer. Additionally, MSI identified a general lack of response to neo-adjuvant therapy employing 5-fluorouracil. Like predictive markers of response to chemotherapy, the role of MSI is likely not exhausted, as chemotherapy regimens need to take into account the peculiar biological and clinical behavior of MSI cancers.
Insights
Microsatellite instability (MSI) in colorectal cancer acts as a diagnostic and prognostic biomarker. MSI testing reveals better patient outcomes and predicts response to therapies like 5-fluorouracil.
Area of Science:
- Oncology
- Molecular Biology
- Translational Science
Background:
- Microsatellite instability (MSI) is a molecular phenotype of colorectal cancers linked to mismatch repair defects.
- MSI represents a successful integration of basic and clinical research, exemplifying translational science.
- Its discovery in the late 20th century opened new avenues for understanding colorectal cancer.
Purpose of the Study:
- To highlight the diagnostic utility of MSI in identifying hereditary nonpolyposis colorectal cancer.
- To underscore the prognostic significance of MSI, indicating a better clinical outcome for affected patients.
- To explore the role of MSI as a predictive marker for chemotherapy response, particularly 5-fluorouracil.
Main Methods:
- The abstract does not detail specific experimental methods.
- It focuses on the conceptual and clinical implications derived from MSI research.
- Analysis of clinical data and molecular phenotypes is implied.
Main Results:
- MSI serves as a crucial diagnostic biomarker for hereditary nonpolyposis colorectal cancer.
- Patients with MSI colorectal cancer generally exhibit a better prognosis.
- MSI indicates a reduced response to neoadjuvant 5-fluorouracil therapy.
Conclusions:
- MSI testing is vital for colorectal cancer diagnosis and prognosis.
- The unique biological and clinical characteristics of MSI cancers necessitate tailored chemotherapy regimens.
- Further research into MSI's role as a predictive marker for diverse chemotherapies is warranted.
Related Concept Videos
01:10Drugs that Destabilize Microtubules
01:15Drugs that Stabilize Microtubules
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase